SCHEMBL25908563

SCHEMBL25908563

Cc1ccc(C(C)(F)F)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.39
PDK1 Q15118 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
PDE2A O00408 1/20 0.38
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MCL1 Q07820 1/20 0.35
RAPGEF4 Q8WZA2 1/20 0.34
RXRA P19793 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
GABRA1 P14867 2/20 0.33
GABRG2 P18507 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1043249 0.84 SMN1; SMN2 (0.45) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL12872215 0.83 PDK1 (0.42) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL803011 0.82 ALDH1A1 (0.39) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL15280202 0.81 SMN1; SMN2 (0.37) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL21995414 0.81 CYP3A4 (0.39) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL29268112 0.81 HSD11B1 (0.41) MAPTPDE2ACYP3A4TSHRMAPK1
SCHEMBL19708930 0.78 PDK1 (0.39) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL16579353 0.78 TDP1 (0.35) PDK2PDK1PDK3PDK4SMN1; SMN2
SCHEMBL5380073 0.77 TDP1 (0.60) SMN1; SMN2TP53MAPTRAB9APDE2A
SCHEMBL22667817 0.77 TDP1 (0.41) SMN1; SMN2TP53MAPTPDE2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234925-A1 GPR52 MODULATORS AND METHODS OF USE GPR52, GPR68, GPR35 PDK2 1380/4885PDK1 1669/4885PDK3 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.